Clearstead Trust LLC Has $69,000 Position in CVS Health Co. (NYSE:CVS)

Clearstead Trust LLC decreased its stake in shares of CVS Health Co. (NYSE:CVS) by 49.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 868 shares of the pharmacy operator’s stock after selling 861 shares during the period. Clearstead Trust LLC’s holdings in CVS Health were worth $69,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Atticus Wealth Management LLC grew its holdings in CVS Health by 149.0% in the 4th quarter. Atticus Wealth Management LLC now owns 366 shares of the pharmacy operator’s stock valued at $29,000 after buying an additional 219 shares in the last quarter. Cornerstone Planning Group LLC grew its position in shares of CVS Health by 111.5% during the 3rd quarter. Cornerstone Planning Group LLC now owns 461 shares of the pharmacy operator’s stock worth $32,000 after purchasing an additional 243 shares in the last quarter. ZRC Wealth Management LLC increased its holdings in shares of CVS Health by 400.0% during the fourth quarter. ZRC Wealth Management LLC now owns 500 shares of the pharmacy operator’s stock worth $39,000 after purchasing an additional 400 shares during the period. Coston McIsaac & Partners raised its position in shares of CVS Health by 42.6% in the fourth quarter. Coston McIsaac & Partners now owns 539 shares of the pharmacy operator’s stock valued at $42,000 after buying an additional 161 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners acquired a new stake in CVS Health during the fourth quarter worth approximately $50,000. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Trading Up 1.4 %

CVS Health stock traded up $0.75 during mid-day trading on Friday, hitting $55.90. 23,946,075 shares of the stock were exchanged, compared to its average volume of 12,498,538. The stock has a market capitalization of $70.18 billion, a price-to-earnings ratio of 9.82, a PEG ratio of 0.88 and a beta of 0.56. CVS Health Co. has a 12 month low of $53.70 and a 12 month high of $83.25. The company has a quick ratio of 0.63, a current ratio of 0.81 and a debt-to-equity ratio of 0.78. The firm’s fifty day simple moving average is $72.77 and its two-hundred day simple moving average is $73.29.

CVS Health (NYSE:CVS) last announced its earnings results on Wednesday, May 1st. The pharmacy operator reported $1.31 earnings per share for the quarter, missing analysts’ consensus estimates of $1.69 by ($0.38). CVS Health had a return on equity of 13.53% and a net margin of 2.03%. The firm had revenue of $88.44 billion for the quarter, compared to the consensus estimate of $89.33 billion. During the same period in the prior year, the business earned $2.20 EPS. CVS Health’s quarterly revenue was up 3.7% on a year-over-year basis. Analysts forecast that CVS Health Co. will post 7.03 EPS for the current year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, May 1st. Shareholders of record on Monday, April 22nd were issued a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.76%. The ex-dividend date was Friday, April 19th. CVS Health’s payout ratio is 46.75%.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on CVS shares. SVB Leerink reiterated a “market perform” rating and set a $60.00 target price (down from $87.00) on shares of CVS Health in a research report on Wednesday. Mizuho decreased their price objective on shares of CVS Health from $86.00 to $72.00 and set a “buy” rating on the stock in a research note on Thursday. StockNews.com downgraded CVS Health from a “buy” rating to a “hold” rating in a report on Thursday, February 15th. Truist Financial reaffirmed a “buy” rating and issued a $66.00 price objective (down from $90.00) on shares of CVS Health in a research note on Thursday. Finally, UBS Group lowered shares of CVS Health from a “buy” rating to a “neutral” rating and decreased their price target for the company from $85.00 to $60.00 in a report on Thursday. Eight analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $80.35.

Insider Transactions at CVS Health

In related news, Director Edward J. Ludwig bought 1,000 shares of the company’s stock in a transaction that occurred on Thursday, May 2nd. The shares were bought at an average price of $53.88 per share, for a total transaction of $53,880.00. Following the transaction, the director now directly owns 21,630 shares of the company’s stock, valued at $1,165,424.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director Edward J. Ludwig acquired 1,000 shares of CVS Health stock in a transaction on Thursday, May 2nd. The stock was purchased at an average price of $53.88 per share, with a total value of $53,880.00. Following the completion of the purchase, the director now owns 21,630 shares of the company’s stock, valued at approximately $1,165,424.40. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Prem S. Shah sold 29,473 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $76.95, for a total value of $2,267,947.35. Following the transaction, the executive vice president now directly owns 39,765 shares in the company, valued at $3,059,916.75. The disclosure for this sale can be found here. Insiders own 0.24% of the company’s stock.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.